In addition to further preclinical studies on third-generation anti-EGFRvIII CAR T cells by multiple groups [113,114,115], recent studies have augmented their approach to increase efficacy and decrease toxicity, including an approach to combine anti-EGFRvIII CAR T cells with anti-EGFR bispecific T cell-engager (BiTE) antibodies to treat EGFR-positive/EGFRvIII-negative GBM [116]. The gene discussed is EGFR; the disease is glioblastoma.